Researchers at Wake Forest Baptist Medical Center are embarking on a project that is so overloaded with sci-fiesque elements that if it were a movie, you might question the screenwriter’s credibility.
The “body on a chip” project will use 3-D printing — or bioprinting — technology to create mini human-organ systems about the size of a quarter to test the body’s response to drugs. It’s funded by a $24 million grant from the Defense Department to develop antidotes to very strong agents in the areas of chemical and biological warfare.
The ultimate goal of bioprinting is to create large, functional, implantable organs that will address the growing gap between viable organ supply and demand for transplants. Along the way, the simpler, mini-versions can be used to more effectively test drugs.
A few groups have been experimenting with bioprinting tissues and organs, but the body-on-a-chip project is unique in connecting the structures together. The chip will be able to test the impact of agents — including intense chemical weapons, more mainstream drugs, and treatments — on the human body. The project offers an alternative to animal testing — which is often inefficient and inaccurate for measuring human responses — and enables the lab to test the full system’s response, rather than just one type of organ.
Scientists started making tissues by hand about 25 years ago. Using a technique known as scaffolding, cells from a patient’s tissue were layered on 3-D molds and grown in an incubator outside the body. Using bioprinting technology, they are now able to feed the same information into a computer to build the tissue.
“Printing came about as a way to scale up the tissues and organs we were already creating by hand,” says Anthony Atala, director of the Wake Forest Institute of Regenerative Medicine in North Carolina and the lead investigator on the project. Bioprinting enables researchers to create tissues with much greater precision and accuracy.
Atala explains the four tissues types in order of complexity: Simplest are flat structures like skin; second are tubular structures, such as blood vessels or windpipes; third are hollow non-tubular organs, such as the stomach, bladder, and uterus; and last and most complex by far are solid organs, such as the heart, kidney, and liver. These have more cells per area, more cell types, and higher nutrition requirements, and they need much more vascularity and blood supply.
To this point, scientists have only implanted the first three types from handmade tissues in patients. No bioprinted structure has been implanted.
The mini-organs are small enough that they don’t require a complex vascular tree to survive. The mini-livers, hearts, lungs, and kidneys are not fully functional native organs, but they mimic the functionality for the testing application.
The Wake Forest lab has developed one machine to bioprint different types of tissues. “It’s like with an inkjet printer, where you have different colors,” says Sang Jin Lee, a coinvestigator on the project. “Here we have different nozzles and different materials and cells.”
The researchers are borrowing from computer microchip and biosensing technology. They will focus on one organ type at a time, beginning with the liver. As each is developed, it will be used to test drug responses individually; once they are completed, they will be connected on the chip to test the full system response.
A small handful of other groups are developing technologies to print tissues, although generally with a focus on individual organs, rather than the full system.
Organovo, a start-up in San Diego, is using bioprinting of tissues to improve research on drugs, with a recent focus on the liver.
“Reliance on animal models and cells in a petri dish [for testing] is problematic, because many diseases can’t get good animal models or don’t behave similarly in petri dishes,” says Organovo CEO Keith Murphy. The company has succeeded in bioprinting liver tissue that lasted 40 days in a dish. Murphy says normally the tissue stops functioning in two days, which is not helpful for testing a drug that is administered for two years.
Organovo is focused on the immediate commercial impact of bioprinting, with testing done on each tissue independently. “We’ve contemplated putting [the parts] together over time, but you don’t need 10 things to study the liver — you need the liver,” explains Murphy.
“You can make living structures act like living tissues,” he says. “You don’t need the full organ to have an impact.”
The Advanced Manufacturing Technology Group at the University of Iowa is bioprinting tissue with this idea in mind. Ibrahim Ozbolat, AMTech codirector and assistant professor of mechanical and industrial engineering, is focused on creating tissue that would accompany — not necessarily replace — the pancreas and produce insulin to help patients with diabetes.
“We’re not interested in making a full natural pancreas,” he says. “We’re working on making something that is large enough and produces enough insulin that is transplantable.”
These projects are all steps along the path toward bioprinting large organs, although that goal and its clinical application is years in the future.
“[Bioprinting organs] is still several billion dollars away,” Murphy says. “If the funding is provided in five years, it could happen quickly. If it takes 20 years, it will be more over that time frame.”
The hope is that as the technologies continue to develop, the manufacturing of organs could help solve the problem of rapidly growing transplant wait-lists.
Atala notes that over two sets of 10 years, the number of patients on wait-lists has doubled, while the number of organs transplanted has increased by only 1 percent — a problem the American Hospital Association has declared a public health crisis.
“This is really what drives us to do this,” he says. “Everything builds on the next step.”
- 1 Democrats Prepare Major Campaign Finance Reform Push
- 2 Bull’s Eye: Here’s the Obamas’ New Neighborhood
- 3 Your One-Stop Shop for Visualizing the Legislative Process
- 4 Smart Ideas: Chinese Debt, Romneycare, and the Problem With Killing Terrorist Leaders
- 5 Why Is the Farm Bill Finally Ripe for Passage?
What We're Following See More »
"The National Highway Traffic Safety Administration identified on Friday the makes and models of 12 million cars and motorcycles that have been recalled because of defective air bag inflators made by Japanese supplier Takata. The action includes 4.3 million Chryslers; 4.5 million Hondas; 1.6 million Toyotas; 731,000 Mazdas; 402,000 Nissans; 383,000 Subarus; 38,000 Mitsubishis; and 2,800 Ferraris. ... Analysts have said it could take years for all of the air bags to be replaced. Some have questioned whether Takata can survive the latest blow."
Homeland Security Secretary Jeh Johnson says 41 Secret Service agents have been disciplined in the fallout of an investigation over the agency's leak of personnel files. The leaker, who has resigned, released records showing that Oversight and Government Reform Chair Jason Chaffetz—who was leading an investigation of Secret Service security lapses—had applied for a job at the agency years before. The punishments include reprimands and suspension without pay. "Like many others I was appalled by the episode reflected in the Inspector General’s report, which brought real discredit to the Secret Service," said Johnson.
Mitt Romney spoke in an interview with the Wall Street Journal about his decision to challenge Donald Trump. “Friends warned me, ‘Don’t speak out, stay out of the fray,’ because criticizing Mr. Trump will only help him by giving him someone else to attack. They were right. I became his next target, and the incoming attacks have been constant and brutal.” Still, "I wanted my grandkids to see that I simply couldn’t ignore what Mr. Trump was saying and doing, which revealed a character and temperament unfit for the leader of the free world.”
"A bill to help Puerto Rico handle its $70 billion debt crisis is facing an uncertain future in the Senate. No Senate Democrats have endorsed a bill backed by House Speaker Paul Ryan and Minority Leader Nancy Pelosi, while some are actively fighting it. ... On the Republican side, senators say they’re hopeful to pass a bill but don’t know if they can support the current legislation — which is expected to win House approval given its backing from leaders in that chamber."
"Congress abandoned the Capitol Thursday for an almost two-week break without addressing how to combat Zika, even as public health officials issue dire warnings about the spread of the mosquito-driven virus with summer approaching. ... Instead of racing to fund efforts to thwart a potential health crisis, lawmakers are treating the Zika debate like regular legislation, approving Thursday the establishment of a House-Senate committee to hammer out differences in their competing bills."